Currently, the prevalence of vertebral pain syndromes in patients from United States and European countries ranges from 14 to 42%. In outpatient back pain occupy one of the leading positions as for the causes of the total complaints. Pain in the lumbosacral region remains one of the most common chronic pain syndromes; prevalence of chronic pain in the back and neck varies from 24 to 56.7%. Pain in the lower back occurs in 7-9 out of 10 members of the adult population, representing, together with acute respiratory diseases leading cause of temporary disability.
Zanaflex is the drug representing the group of centrally acting muscle relaxants with the main active ingredient of tizanidine. The medication is mainly produced in the form of 2 mg or 4 mg tablets. The treatment of muscle relaxants begins with the common therapeutic dose and continues throughout the retention of pain. Generally, the treatment lasts for several weeks.
One of the most effective and safe drugs of this group is Sirdalud, the international non-proprietary name - tizanidine. It is proved that the painful muscle spasm addition to standard therapy, muscle relaxants, leads to a more rapid regression of pain, muscle tension and improve mobility of the spine. Clinical studies comparing monotherapy with combination therapy of NSAIDs NSAIDs and tizanidine, demonstrated the superiority of the latter in efficiency.